Ernexa Therapeutics Inc. Foreign Currency Transaction Gain (Loss), before Tax
Ernexa Therapeutics Inc. (ERNA) reported Foreign Currency Transaction Gain (Loss), before Tax of -$16.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2021-03-11
- Ernexa Therapeutics Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2014-09-30 was $31.00K.
- Ernexa Therapeutics Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2014-06-30 was -$27.00K, a 437.50% decline year-over-year.
- Ernexa Therapeutics Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2014-03-31 was $24.00K, a 242.86% increase year-over-year.
- Ernexa Therapeutics Inc. foreign currency transaction gain (loss), before tax for the quarter ending 2013-09-30 was -$8.00K.
- Ernexa Therapeutics Inc. foreign currency transaction gain (loss), before tax for fiscal 2020 was -$16.00K.
- Ernexa Therapeutics Inc. foreign currency transaction gain (loss), before tax for fiscal 2019 was -$48.00K, a 217.07% decline from fiscal 2018.
- Ernexa Therapeutics Inc. foreign currency transaction gain (loss), before tax for fiscal 2018 was $41.00K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 3 month as first filed | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month as first filed | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month as first filed | Foreign Currency Transaction Gain (Loss), before Tax 12 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | -$16.00K 10-K · filed 2021-03-11 | |||||||
| 2019-12-31 | -$48.00K 10-K · filed 2021-03-11 | $48.00K 10-K · filed 2020-03-19 | ||||||
| 2018-12-31 | $41.00K 10-K · filed 2020-03-19 | |||||||
| 2014-09-30 | $31.00K 10-Q · filed 2014-11-07 | $4.00K derived: sum of 2 quarters · filed 2014-11-07 | $27.00K 10-Q · filed 2014-11-07 | |||||
| 2014-06-30 | -$27.00K 10-Q · filed 2014-08-14 | -$3.00K 10-Q · filed 2014-08-14 | ||||||
| 2014-03-31 | $24.00K 10-Q · filed 2014-05-15 | |||||||
| 2013-09-30 | -$8.00K 10-Q · filed 2014-11-07 | $0.00 derived: sum of 2 quarters · filed 2014-11-07 | $7.00K 10-Q · filed 2014-11-07 | |||||
| 2013-06-30 | $8.00K 10-Q · filed 2014-08-14 | $15.00K 10-Q · filed 2014-08-14 | ||||||
| 2013-03-31 | $7.00K 10-Q · filed 2014-05-15 | |||||||
| 2012-09-30 | -$13.00K 10-Q · filed 2013-11-14 | $13.00K 10-Q · filed 2012-11-09 | $1.00K derived: sum of 2 quarters · filed 2013-11-14 | -$18.00K 10-Q · filed 2013-11-14 | $18.00K 10-Q · filed 2012-11-09 | |||
| 2012-06-30 | $14.00K 10-Q · filed 2013-08-14 | -$5.00K 10-Q · filed 2013-08-14 | $5.00K 10-Q · filed 2012-08-14 | |||||
| 2012-03-31 | -$19.00K 10-Q · filed 2013-05-13 | |||||||
| 2011-09-30 | $5.00K 10-Q · filed 2012-11-09 | $31.00K derived: sum of 2 quarters · filed 2012-11-09 | $30.00K 10-Q · filed 2012-11-09 | |||||
| 2011-06-30 | $26.00K 10-Q · filed 2012-08-14 | $35.00K 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |